Back to top
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com Most Recent Articles
Verizon Surpasses Q4 Earnings Estimates on Healthy Revenue Growth
Analyst Blog
by Zacks Equity Research
VZ beats Q4 estimates as broadband growth and fiber densification boost revenue despite higher expenses.
VZPositive Net Change AKAMNegative Net Change ANETNegative Net Change PINSNegative Net Change
communications earnings iot mobile tech-stocks
Modine Gears Up to Report Q3 Earnings: What's in the Cards?
Analyst Blog
by Zacks Equity Research
MOD is set to report Q3 results on Feb. 4, with EPS seen up 7.6% and revenues up 23.8%, as Climate Solutions strength offsets Performance Technologies weakness.
BWAPositive Net Change MGAPositive Net Change MODPositive Net Change RIVNNegative Net Change
auto-tires-trucks earnings
Here's Why West Pharmaceutical (WST) Is a Great 'Buy the Bottom' Stock Now
Tale of the Tape
by Zacks Equity Research
West Pharmaceutical (WST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
WSTNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now
Tale of the Tape
by Zacks Equity Research
Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
VCYTPositive Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Should You Buy First Bancorp (FBP) After Golden Cross?
Tale of the Tape
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FBPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Simmons First National (SFNC) Just Flashed Golden Cross Signal: Do You Buy?
Tale of the Tape
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SFNCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Wall Street Analysts Think Forestar Group (FOR) Could Surge 27.61%: Read This Before Placing a Bet
Tale of the Tape
by Zacks Equity Research
The mean of analysts' price targets for Forestar Group (FOR) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FORPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Here's Why AngioDynamics (ANGO) Is a Great 'Buy the Bottom' Stock Now
Tale of the Tape
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for AngioDynamics (ANGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ANGONegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Does Adtalem (ATGE) Have the Potential to Rally 46.83% as Wall Street Analysts Expect?
Tale of the Tape
by Zacks Equity Research
The mean of analysts' price targets for Adtalem (ATGE) points to a 46.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ATGENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Here's Why Roku (ROKU) Could be Great Choice for a Bottom Fisher
Tale of the Tape
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Roku (ROKU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ROKUNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement